{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:04:25Z","timestamp":1790611465673,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2021.09.013","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T12:18:01Z","timestamp":1637583481000},"page":"398-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations versus alternative antibiotics in adults with hospital-acquired pneumonia or ventilator-associated pneumonia: an integrated analysis of three randomised controlled trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Huamei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-3161","authenticated-orcid":false,"given":"Shao-Huan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Peng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-0780","authenticated-orcid":false,"given":"Li-Chin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Hsing","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.09.013_bib0001","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.09.013_bib0002","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2021.09.013_bib0003","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s001340000640","article-title":"Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia","volume":"27","author":"Dupont","year":"2001","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2021.09.013_bib0004","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2021.09.013_bib0005","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/01.CCM.0000055381.70829.94","article-title":"Treatment of ventilator-associated pneumonia: get it right from the start","volume":"31","author":"Kollef","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2021.09.013_bib0006","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2021.09.013_bib0008","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/resp.13115","article-title":"The respiratory threat posed by multidrug resistant Gram-negative bacteria","volume":"22","author":"Rodrigo-Troyano","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.jgar.2021.09.013_bib0009","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1186\/s12879-019-4461-x","article-title":"Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case\u2013control and cohort study","volume":"19","author":"Cienfuegos-Gallet","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0010","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","article-title":"Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis","volume":"47","author":"Du","year":"2019","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jgar.2021.09.013_bib0011","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s10096-017-3039-z","article-title":"The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs","volume":"36","author":"Borgatta","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0012","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0013","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime\u2013avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0014","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.09.013_bib0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime\u2013avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0016","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0017","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane\u2013tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2021.09.013_bib0018","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem\u2013vaborbactam vs piperacillin\u2013tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2021.09.013_bib0019","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime\u2013avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0021","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0022","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)","author":"Titov","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14787210.2018.1429912","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2021.09.013_bib0024","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1590\/1806-9282.64.03.253","article-title":"Efficacy and safety of ceftazidime\u2013avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): a meta-analysis of randomized controlled trials","volume":"64","author":"Zhang","year":"1992","journal-title":"Rev Assoc Med Bras"},{"key":"10.1016\/j.jgar.2021.09.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.11.015","article-title":"The use of ceftolozane\u2013tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections\u2014a meta-analysis of randomized controlled trials","volume":"55","author":"Cheng","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.09.013_bib0026","doi-asserted-by":"crossref","first-page":"e19960","DOI":"10.1097\/MD.0000000000019960","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: a meta-analysis of randomized controlled trials","volume":"99","author":"Lu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2021.09.013_bib0027","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2021.09.013_bib0028","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","volume":"72","author":"Karlowsky","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106111","article-title":"Assessment of the in vitro activity of ceftazidime\/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015\u20132017)","volume":"56","author":"Rossolini","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.09.013_bib0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/mdr.2020.0217","article-title":"Antimicrobial activity of ceftazidime\u2013avibactam, ceftolozane\u2013tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates from United States medical centers in 2016\u20132018","volume":"27","author":"Sader","year":"2021","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2021.09.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106045","article-title":"In vitro activity of ceftazidime\u2013avibactam against Gram-negative isolates collected in 18 European countries, 2015\u20132017","volume":"56","author":"Stone","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.09.013_bib0032","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3855\/jidc.12368","article-title":"Activity of ceftolozane\/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon","volume":"14","author":"Araj","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.jgar.2021.09.013_bib0033","first-page":"2164","article-title":"In vitro activity of ceftolozane\/tazobactam alone and in combination with amikacin against MDR\/XDR Pseudomonas aeruginosa isolates from Greece","volume":"75","author":"Galani","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.09.013_bib0034","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/jac\/dkaa278","article-title":"Susceptibility trends of ceftolozane\/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012\u201318","volume":"75","author":"Sader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.09.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02203-19","article-title":"Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 phase 3 trial of imipenem\u2013cilastatin\u2013relebactam versus colistin plus imipenem\u2013cilastatin in patients with imipenem-nonsusceptible bacterial infections","volume":"64","author":"Kaye","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.09.013_bib0036","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.09.013_bib0037","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime\u2013avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.09.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105891","article-title":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications","volume":"55","author":"Maraolo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.09.013_bib0039","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2017.11.003","article-title":"Ceftolozane\/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes","volume":"51","author":"Dietl","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.09.013_bib0040","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:03Z","timestamp":1761991263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":40,"alternative-id":["S2213716521002381"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.09.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations versus alternative antibiotics in adults with hospital-acquired pneumonia or ventilator-associated pneumonia: an integrated analysis of three randomised controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}